Sirtex shares soar on liver cancer treatment

Oli Scarff/Getty Images

Sirtex Medical announced that the results of trials for its liver cancer treatment had been well accepted by the medical community.

Its shares were up 15% to $30.70 in early trade.

Shares in Sirtex Medical have been on a tear since the biotech announced last month an improved survival rates for liver cancer patients using its radioactive spheres treatment.

A study shows an additional 7.9 months to 20.5 months in the survival of liver cancer patients whose treatment included SIR-Spheres.

NOW WATCH: Briefing videos

Business Insider Emails & Alerts

Site highlights each day to your inbox.

Follow Business Insider Australia on Facebook, Twitter, LinkedIn, and Instagram.